Welcome to our dedicated page for Aridis Pharmaceuticals SEC filings (Ticker: ARDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
aridis is a privately held infectious diseases focused company in san jose, ca, usa. aridis’ advanced formulation and delivery technologies are combined with proprietary products portfolio to create potent drug candidates that are packaged into convenient to administer, "ready-to-use" formats.Aridis Pharmaceuticals reports a Schedule 13G/A showing Armistice Capital, LLC and Steven Boyd beneficially own 5,096,251 shares, representing 11.43% of the common stock (CUSIP 040334104). The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and Mr. Boyd, as managing member, may be deemed to beneficially own the shares. The Master Fund is identified as the direct holder and is described as having the right to receive dividends or sale proceeds.